{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:49:08Z","timestamp":1740142148115,"version":"3.37.3"},"reference-count":28,"publisher":"Bentham Science Publishers Ltd.","issue":"9","funder":[{"DOI":"10.13039\/501100006739","name":"Capital Foundation of Medical Development","doi-asserted-by":"publisher","award":["2009-2055"],"award-info":[{"award-number":["2009-2055"]}],"id":[{"id":"10.13039\/501100006739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2019,10,4]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>This study aimed to re-establish a Population Pharmacokinetic (PPK) model of oral phenytoin\nto further optimize the individualized medication regimen based on our previous research.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Patients with intracranial malignant tumor requiring craniotomy were prospectively enrolled according to\nthe inclusion criteria. Genotypes of CYP2C9*1 or *3 and CYP2C19*1, *2 or *3 were determined by real time PCR\n(TaqMan probe) method. Serum concentrations of phenytoin on the 4th and 7th day after oral administration were\ndetermined using fluorescence polarization immunoassay. The PPK parameters were estimated using Nonlinear\nMixed Effects Models (NONMEM) and internal validation was performed using bootstraps. The predictive performance\nof the final model was evaluated by Normalized Predictive Distribution Errors (NPDEs) and diagnostic goodness-\nof-fit plots.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of 390 serum samples were collected from 170 patients in PPK model building group. The population\ntypical values for Vm, Km and the apparent volume of distribution (V) in the final model were 17.5 mg\/h, 6.41\nmg\/L and 54.8 L, respectively. Internal validation by bootstraps showed that the final model was stable and reliable.\nNPDEs with a normal distribution and a scatterplot with symmetrical distribution showed that the final model had\ngood predictive capability. Individualized dose regimens of additional 40 patients in the external validation group\nwere designed by the present final PPK model. The percentages of patients with serum concentrations within the\ntherapeutic range were 61.53% (24\/39) on the 4th day and 94.87% (37\/39) on the 7th day, which were higher than the\n39.33% (59\/150) and 52.10% (87\/167) of above 170 patients (P &lt; 0.0001).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The present PPK final model for oral phenytoin may be used to further optimize phenytoin individualized\ndose regimen to prevent early seizure in patients after brain injury if patient characteristics meet those of the\npopulation studied.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200220666190913115837","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T15:00:51Z","timestamp":1568386851000},"page":"756-764","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Evolution of Population Pharmacokinetic Model of Oral Phenytoin for Early Seizure Prophylaxis Post-Craniotomy"],"prefix":"10.2174","volume":"20","author":[{"given":"Zhongdong","family":"Li","sequence":"first","affiliation":[{"name":"Electric Power Teaching Hospital, Capital Medical University, Beijing 100073, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Air Force Clinical Department, Chinese PLA General Hospital, Beijing 100000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangmin","family":"Ji","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Jin","sequence":"additional","affiliation":[{"name":"Air Force Clinical School, AnHui Medical University, HeFei 230032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiqin","family":"Song","sequence":"additional","affiliation":[{"name":"Electric Power Teaching Hospital, Capital Medical University, Beijing 100073, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0090-3019(89)90067-0","volume":"31","author":"Lee S.T.","year":"1989","unstructured":"Lee S.T.; Lui T.N.; Chang C.N.; Cheng W.C.; Wang D.J.; Heimburger R.F.; Lin C.G.; Prophylactic anticonvulsants for prevention of immediate and early postcraniotomy seizures. Surg Neurol 1989,31(5),361-364","journal-title":"Surg Neurol"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.annemergmed.2003.09.016","volume":"43","author":"Young K.D.","year":"2004","unstructured":"Young K.D.; Okada P.J.; Sokolove P.E.; Palchak M.J.; Panacek E.A.; Baren J.M.; Huff K.R.; McBride D.Q.; Inkelis S.H.; Lewis R.J.; A randomized, double-blinded, placebo-controlled trial of phenytoin for the prevention of early posttraumatic seizures in children with moderate to severe blunt head injury. Ann Emerg Med 2004,43(4),435-446","journal-title":"Ann Emerg Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJM199008233230801","volume":"323","author":"Temkin N.R.","year":"1990","unstructured":"Temkin N.R.; Dikmen S.S.; Wilensky A.J.; Keihm J.; Chabal S.; Winn H.R.; A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990,323(8),497-502","journal-title":"N Engl J Med"},{"key":"ref=4","author":"Schierhout G.","year":"2000","unstructured":"Schierhout G.; Roberts I.; Anti-epileptic drugs for preventing seizures following acute traumatic brain injury. Cochrane Database Syst Rev 2000(2)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1212\/01.WNL.0000031432.05543.14","volume":"60","author":"Chang B.S.","year":"2003","unstructured":"Chang B.S.; Lowenstein D.H.; Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003,60(1),10-16","journal-title":"Neurology"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/01720610-201212000-00002","volume":"25","author":"DeDea L.","year":"2012","unstructured":"DeDea L.; Phenytoin or levetiracetam for seizure prophylaxis in TBI. JAAPA 2012,25(12),11","journal-title":"JAAPA"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2146\/ajhp120203","volume":"70","author":"Torbic H.","year":"2013","unstructured":"Torbic H.; Forni A.A.; Anger K.E.; Degrado J.R.; Greenwood B.C.; Use of antiepileptics for seizure prophylaxis after traumatic brain injury. Am J Health Syst Pharm 2013,70(9),759-766","journal-title":"Am J Health Syst Pharm"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11060-014-1564-5","volume":"120","author":"de Oliveira J.A.","year":"2014","unstructured":"de Oliveira J.A.; Santana I.A.; Caires I.Q.; Caires-Lima R.; Miranda V.C.; Prot\u00e1sio B.M.; Rocha L.S.; Braga H.F.; Mencarini A.M.; Teixeira M.J.; Castro L.H.; Feher O.; Antiepileptic drug prophylaxis in primary brain tumor patients: is current practice in agreement to the consensus? J Neurooncol 2014,120(2),399-403","journal-title":"J Neurooncol"},{"key":"ref=9","first-page":"448","volume":"40","author":"Lee S.Y.","year":"2007","unstructured":"Lee S.Y.; Lee S.T.; Kim J.W.; Contributions of CYP2C9\/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. J Biochem Mol Biol 2007,40(3),448-452","journal-title":"J Biochem Mol Biol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2710.2006.00712.x","volume":"31","author":"Yukawa E.","year":"2006","unstructured":"Yukawa E.; Mamiya K.; Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach. J Clin Pharm Ther 2006,31(3),275-282","journal-title":"J Clin Pharm Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/tpj.2015.45","volume":"16","author":"Ortega-V\u00e1zquez A.","year":"2016","unstructured":"Ortega-V\u00e1zquez A.; Dorado P.; Fricke-Galindo I.; Jung-Cook H.; Monroy-Jaramillo N.; Mart\u00ednez-Ju\u00e1rez I.E.; Familiar-L\u00f3pez I.; Pe\u00f1as-Lled\u00f3 E.; LLerena, A.; L\u00f3pez-L\u00f3pez, M. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy. Pharmacogenomics J 2016,16(3),286-292","journal-title":"Pharmacogenomics J"},{"key":"ref=12","first-page":"542","volume":"96","author":"Caudle K.E.","year":"2014","unstructured":"Caudle K.E.; Rettie A.E.; Whirl-Carrillo M.; Smith L.H.; Mintzer S.; Lee M.T.; Klein T.E.; Callaghan J.T.; Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther  [J].2014,96(5),542-548","journal-title":"Clin Pharmacol Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/FTD.0000000000000128","volume":"37","author":"Yamamoto Y.","year":"2015","unstructured":"Yamamoto Y.; Takahashi Y.; Imai K.; Miyakawa K.; Ikeda H.; Ueda Y.; Yamaguchi T.; Nasu H.; Ohtani H.; Shigematsu H.; Kagawa Y.; Inoue Y.; Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes. Ther Drug Monit 2015,37(2),229-235","journal-title":"Ther Drug Monit"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.drup.2008.03.002","volume":"11","author":"van Schaik R.H.","year":"2008","unstructured":"van Schaik R.H.; CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 2008,11(3),77-98","journal-title":"Drug Resist Updat"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4103\/0028-3886.156281","volume":"63","author":"Sharma S.","year":"2015","unstructured":"Sharma S.; Tabassum F.; Dwivedi P.; Agarwal R.; Kushwaha S.; Bala K.; Grover S.; Baghel R.; Kukreti R.; Tripathi C.B.; Critical appraisal of serum phenytoin variation with patient characteristics in a North Indian population. Neurol India 2015,63(2),202-208","journal-title":"Neurol India"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/00007691-199808000-00010","volume":"20","author":"Frame B.","year":"1998","unstructured":"Frame B.; Beal S.L.; Non-steady state population kinetics of intravenous phenytoin. Ther Drug Monit 1998,20(4),408-416","journal-title":"Ther Drug Monit"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/00007691-200410000-00012","volume":"26","author":"Hung C.C.","year":"2004","unstructured":"Hung C.C.; Lin C.J.; Chen C.C.; Chang C.J.; Liou H.H.; Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9\/CYP2C19 polymorphisms. Ther Drug Monit 2004,26(5),534-540","journal-title":"Ther Drug Monit"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2174\/1389200217666160513132716","volume":"17","author":"Li Z.D.","year":"2016","unstructured":"Li Z.D.; Liu M.; Li L.; Wan J.H.; Lei Z.; Huang Y.A.; Population pharmacokinetics of phenytoin based on NONMEM in patients with intracranial tumor during the first week of post-craniotomy. Curr Drug Metab 2016,17(7),721-728","journal-title":"Curr Drug Metab"},{"key":"ref=19","first-page":"489","volume":"69","author":"Tanaka J.","year":"2013","unstructured":"Tanaka J.; Kasai H.; Shimizu K.; Shimasaki S.; Kumagai Y.; Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers. Eur J Clin Pharmacol 2013,69(3),489-497","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2133\/dmpk.20.107","volume":"20","author":"Taguchi M.","year":"2005","unstructured":"Taguchi M.; Hongou K.; Yagi S.; Miyawaki T.; Takizawa M.; Aiba T.; Hashimoto Y.; Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients. Drug Metab Pharmacokinet 2005,20(2),107-112","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=21","first-page":"37","volume":"8","author":"Ebrahimi E.S.M.Z.S.E.M.S.P.","year":"2009","unstructured":"Ebrahimi E.S.M.Z.S.E.M.S.P.; Salehifar E.; Zohrabi M.; Eshghi S.; Saeedi M.; Ebrahimi P.; Different pharmacokinetic parameters of phenytoin in Iranian Outpatients: Need to optimize the current dosage administration. Iran J Pharm Res 2009,8(1),37-45","journal-title":"Iran J Pharm Res"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1248\/bpb.19.444","volume":"19","author":"Odani A.","year":"1996","unstructured":"Odani A.; Hashimoto Y.; Takayanagi K.; Otsuki Y.; Koue T.; Takano M.; Yasuhara M.; Hattori. H.; Furusho, K.; Inui, K. Population pharmaco- kinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biol Pharm Bull 1996,19(3),444-448","journal-title":"Biol Pharm Bull"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.arcmed.2004.11.006","volume":"36","author":"Deleu D.","year":"2005","unstructured":"Deleu D.; Aarons L.; Ahmed I.A.; Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients. Arch Med Res 2005,36(1),49-53","journal-title":"Arch Med Res"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00045391-200007010-00003","volume":"7","author":"Kodama H.","year":"2000","unstructured":"Kodama H.; Kodama Y.; Shinozawa S.; Kanemaru R.; Todaka K.; Mitsuyama Y.; Effect of temperature on binding characteristics of phenytoin to serum proteins in monotherapy adult patients with epilepsy. Am J Ther 2000,7(1),11-15","journal-title":"Am J Ther"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1097\/CCM.0b013e318292316c","volume":"41","author":"Empey P.E.","year":"2013","unstructured":"Empey P.E.; Velez de Mendizabal N.; Bell M.J.; Bies R.R.; Anderson K.B.; Kochanek P.M.; Adelson P.D.; Poloyac S.M.; Pediatric TBI Consortium: Hypothermia Investigators. Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury. Crit Care Med 2013,41(10),2379-2387","journal-title":"Crit Care Med"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1097\/CCM.0b013e31829641ca","volume":"41","author":"Agbeko R.S.","year":"2013","unstructured":"Agbeko R.S.; Forsyth R.; High level alert! Modeling temperature and phenytoin: appropriate risk management or virtual reality? Crit Care Med 2013,41(10),2454-2455","journal-title":"Crit Care Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3389\/fgene.2012.00318","volume":"3","author":"Lee S.J.","year":"2013","unstructured":"Lee S.J.; Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine. Front Genet 2013,3,318","journal-title":"Front Genet"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2217\/14622416.9.6.691","volume":"9","author":"Chen L.","year":"2008","unstructured":"Chen L.; Qin S.; Xie J.; Tang J.; Yang L.; Shen W.; Zhao X.; Du J.; He G.; Feng G.; He L.; Xing Q.; Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 2008,9(6),691-702","journal-title":"Pharmacogenomics"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/174852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T08:20:00Z","timestamp":1574929200000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/174852\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,10,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200220666190913115837","relation":{},"ISSN":["1389-2002"],"issn-type":[{"type":"print","value":"1389-2002"}],"subject":[],"published":{"date-parts":[[2019,10,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}